Overview
September 25-26, 2009
New York, NY
International Congress for Lung Cancer, and Head & Neck Cancer
Program Director:
Chandra P. Belani, MD, Miriam Beckner Professor of Medicine,
Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Deputy Director, Penn State Cancer Institute, Hershey, PA
September 25-26, 2009 – New York Marriott East Side, 525 Lexington Avenue at 49th Street
New York, NY 10017 – Phone: (800) 242-8684
Program Committee
Chandra P. Belani, MD
Miriam Beckner Professor of Medicine,
Penn State Milton S. Hershey Medical Center,
Deputy Director, Penn State Cancer Institute, Hershey, PA
Walter Curran, MD
Lawrence W. Davis Professor and Chair of Radiation Oncology,
Department of Radiation Oncology, Chief Medical Officer,
Winship Cancer Institute, Atlanta, GA
Fadlo Khuri, MD
Professor of Hematology and Oncology,
Associate Director, Clinical & Translational Research,
Emory Winship Cancer Institute, Atlanta, GA
Suresh Ramalingam, MD
Associate Professor of Hematology/Oncology,
Chief of Thoracic Medical Oncology,
Emory Winship Cancer Institute, Atlanta, GA
Jointly sponsored by
* International Cancer Network (and Postgraduate Institute for Medicine
* For more information visit: www.Internationalcancernetwork.com
Educational Grants
We are proud to acknowledge the following for their generous support of this activity:
Genentech BioOncology
Lilly USA, LLC
Sanofi-Aventis
Bristol Myers Squibb/
ImClone Systems
Target Audience
This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, researchers and registered oncology nurses interested in new developments for treatment of lung cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows, nurses and pharmacists are also invited to attend.
Statement of Need/Program Overview
This Symposium is intended to provide comprehensive updates on biology, diagnosis, screening, and management of lung cancer. Paradigm shift in the treatment options of non-small-cell lung cancer and small-cell lung cancer will be discussed. This meeting will facilitate interaction among oncologists and researchers interested in development of novel therapeutics for treatment of lung cancer. In addition to multimodality therapy, adjuvant therapy and surgery, this symposium will present data of most promising emerging agents currently in development for the treatment of lung cancer. The format will include didactic lectures from known thought leaders, questions and answer session, and ample opportunity for participant interaction with faculty. In-depth discussion of antiangiogenic agents, inhibitors of EGFR pathways and drugs that target multiple signaling pathways will also be given significant focus. Emerging data from ongoing clinical research will be presented.